Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER vs ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Plasma-Lyte 148 and Dextrose 5% is an intravenous solution that provides maintenance fluid, electrolytes, and calories. Dextrose provides energy and prevents ketosis. Plasma-Lyte 148 contains electrolytes (sodium, potassium, magnesium, calcium, chloride, acetate, gluconate) to replace losses and maintain acid-base balance.
Intravenous solution providing electrolytes (sodium, potassium, magnesium, chloride, acetate, phosphate) and dextrose for caloric supply. Acetate and phosphate serve as bicarbonate precursors to buffer metabolic acids. Dextrose provides energy and protein-sparing effects.
For use as an intravenous source of water, electrolytes, and calories in patients who require fluid and electrolyte replacement and caloric intake,Off-label: treatment and prevention of hypovolemia, maintenance of fluid and electrolyte balance in perioperative settings
Source of electrolytes, calories, and water for hydration in patients with or without carbohydrate deficiency,Maintenance and replacement of fluid and electrolyte losses in pediatric patients,Treatment of hypophosphatemia,Off-label: Total parenteral nutrition component
IV infusion at a rate of 10-20 m L/kg/hour, not to exceed 100 m L/hour in adults without cardiac or renal compromise; adjust based on fluid status and serum electrolytes.
Intravenous infusion, rate determined by patient's fluid and electrolyte needs; typical adult dose: 1-2 L per 24 hours, adjusted based on clinical status.
Not applicable as it is a balanced electrolyte solution with dextrose. Components distribute and are eliminated rapidly; dextrose half-life ~15-30 minutes in normoglycemia.
Dextrose has a half-life of approximately 1.5–3 hours in patients with normal glucose metabolism; in renal failure, electrolyte half-lives may be prolonged. The half-life of sodium is about 2–4 hours, and potassium 2–6 hours, depending on renal function.
Dextrose is metabolized via glycolysis and the citric acid cycle to carbon dioxide and water, producing energy. Acetate and gluconate are metabolized in the liver and tissues to bicarbonate. Electrolytes are not metabolized but are excreted or reutilized.
Dextrose is metabolized via glycolysis to pyruvate then enters the TCA cycle. Acetate is metabolized via TCA cycle to bicarbonate. Phosphate is excreted renally or incorporated into ATP and other compounds.
Components are excreted renally. Dextrose is metabolized; electrolytes are eliminated via kidneys (sodium, chloride, acetate, gluconate, magnesium, potassium). No biliary or fecal elimination.
Electrolytes are primarily excreted via renal pathways; dextrose is metabolized to CO2 and water, with negligible renal excretion. Specifically, sodium, potassium, magnesium, chloride, acetate, and gluconate are eliminated by the kidneys, with over 90% of infused electrolytes excreted renally.
Electrolytes and dextrose have negligible protein binding (<1%). No significant binding.
Sodium, potassium, chloride, magnesium, and acetate have negligible protein binding (<5%); calcium is ~45% bound to albumin; gluconate binding is minimal.
Vd approximates extracellular fluid volume: ~0.15-0.25 L/kg for electrolyte components; dextrose distributes into total body water (~0.6 L/kg).
Electrolytes distribute into total body water, approximately 0.6 L/kg for adults; dextrose distributes into extracellular fluid (~0.2 L/kg) but is rapidly taken up by cells.
Intravenous: 100% (by definition). Not administered via other routes.
Intravenous: 100% bioavailability.
If GFR < 30 m L/min, reduce infusion rate by 50% and monitor potassium and phosphate levels closely; avoid in severe renal impairment if hyperkalemia or hyperphosphatemia is present.
Contraindicated in severe renal impairment (GFR <30 m L/min) due to risk of hyperkalemia and fluid overload; for GFR 30-50 m L/min, use with caution and monitor potassium and fluid status.
No specific Child-Pugh-based adjustment required; use with caution in severe hepatic impairment due to risk of fluid overload and electrolyte disturbances.
No specific dose adjustment for Child-Pugh class; use with caution in severe hepatic impairment due to risk of fluid overload and electrolyte imbalances.
Neonates and children: IV infusion at 5-10 m L/kg/hour, titrated to clinical need; maximum rate 20 m L/kg/hour; monitor electrolytes frequently.
Intravenous infusion at a rate of 100-150 m L/kg/day for maintenance, adjusted based on weight, clinical condition, and electrolyte requirements.
Start at lower infusion rate (5-10 m L/kg/hour) due to age-related decline in renal function; reassess fluid status regularly to avoid volume overload.
Use with caution due to decreased renal function; start at lower infusion rates (e.g., 0.5-1 L per 24 hours) and monitor fluid and electrolyte status closely.
Not approved for use in patients with known hypersensitivity to any component. Not for use as a primary source of nutrition in neonates or low birth weight infants due to risk of aluminum toxicity.
Not for use in patients with intracranial or intraspinal hemorrhage, or in patients with known hypersensitivity to any component. Do not administer simultaneously with blood products through the same set due to risk of hemolysis.
Risk of fluid overload and electrolyte disturbances, especially in patients with renal impairment, heart failure, or severe dehydration,May cause hyperglycemia, particularly in diabetic patients,Monitor serum electrolytes, blood glucose, and fluid balance during infusion,Aluminum toxicity with prolonged use in renal impairment,Do not administer simultaneously with blood products through same IV line
Risk of fluid overload, electrolyte disturbances, and hyperglycemia in patients with impaired renal function, cardiac failure, or diabetes,Use with caution in patients with severe hepatic disease (risk of lactic acidosis from acetate),Monitoring of serum electrolytes, glucose, fluid balance, and acid-base status is required,Avoid extravasation: risk of tissue necrosis
Hypersensitivity to any component,Clinically significant hyperglycemia,Severe hyponatremia, hyperkalemia, or hypercalcemia,Patients with anuria or severe oliguria not due to hypovolemia
Hyperkalemia, hypernatremia, hyperphosphatemia, hypocalcemia,Severe metabolic alkalosis or lactic acidosis,Anuria or severe oliguria,Addison's disease (risk of hyperkalemia),Known hypersensitivity to any component
No direct food interactions. However, dextrose content may affect blood glucose; patients with diabetes should monitor glucose levels closely and adjust insulin/oral hypoglycemic agents as directed. Use with caution in patients on sodium or potassium-modifying diets.
No specific food interactions. Patients should maintain a balanced diet as tolerated, but sodium and potassium intake may need monitoring or adjustment based on electrolyte status. Avoid excessive ingestion of high-sodium or high-potassium foods unless directed by clinician.
Plasma-Lyte 148 and Dextrose 5% is an intravenous electrolyte and carbohydrate solution. At therapeutic doses, no direct fetal toxicity or teratogenicity is expected as electrolytes and dextrose are physiological substances. However, careful monitoring is required during pregnancy to avoid fluid overload, electrolyte imbalances, or hyperglycemia, which could indirectly affect fetal development. No specific trimester-specific risks are identified.
Dextrose and electrolyte solutions are generally considered safe in pregnancy. Dextrose is a physiologic nutrient; no teratogenic effects are expected. Electrolytes are essential ions and do not pose fetal risk when administered appropriately. Hyperglycemia from excessive dextrose may be associated with fetal macrosomia, neonatal hypoglycemia, and other metabolic disturbances, particularly in diabetic pregnancies. No specific trimester risks are identified for isotonic balanced solutions.
Plasma-Lyte 148 and Dextrose 5% is compatible with breastfeeding. Electrolytes and dextrose are normal blood components that are transferred into breast milk in small amounts, not expected to cause adverse effects in the infant. M/P ratio is not applicable as it is a mixture of physiological substances.
Dextrose and electrolytes are normal constituents of breast milk. Infusion of ISOLYTE H with 5% dextrose does not alter milk composition or supply significantly. No adverse effects on breastfed infants are anticipated. The M/P ratio is not applicable as these are endogenous substances; no accumulation expected.
Pharmacokinetic changes during pregnancy (increased plasma volume, altered renal function) may require adjustments in infusion rate and total volume to maintain electrolyte and glucose homeostasis. Dose should be individualized based on maternal weight, clinical status, and laboratory values; no fixed dose adjustment is required.
No specific dose adjustments for pregnancy; however, avoid excessive dextrose administration to prevent maternal hyperglycemia and fetal metabolic complications. Use with caution in gestational diabetes or preeclampsia; consider lower dextrose concentrations or rate adjustments based on maternal blood glucose and electrolyte levels.
PLASMA-LYTE 148 and Dextrose 5% is an isotonic solution containing electrolytes and dextrose. Use within 24 hours of spiking the container. Avoid administering through the same line as blood products due to risk of hemolysis from electrolyte content. Monitor serum glucose, electrolytes, and fluid balance, especially in patients with impaired renal function, diabetes, or heart failure. The solution has a p H of ~5.5; consider compatibility with co-administered drugs.
ISOLYTE H with Dextrose 5% is a hypertonic solution (approx. 480 m Osm/L) used for fluid and electrolyte replacement in patients with hypochloremic metabolic alkalosis and fluid losses. It should be administered through a central line due to its high osmolarity. Monitor serum electrolytes, glucose, and acid-base status. Do not administer if solution is discolored or contains particulate matter.
This solution provides fluids and sugar to help maintain hydration and energy.,Tell your healthcare provider if you have diabetes, heart problems, or kidney disease.,You may experience swelling, shortness of breath, or changes in urination; report these immediately.,Your blood sugar and electrolyte levels will be monitored during treatment.,Do not use this solution if it is cloudy, discolored, or contains particles.
This IV solution provides fluids, electrolytes, and calories to help correct imbalances caused by illness or surgery.,Tell your healthcare provider if you have a history of heart failure, kidney disease, or diabetes, as this solution may affect these conditions.,You may experience discomfort at the IV site; report any pain, redness, or swelling immediately.,Regular blood tests will be needed to monitor your electrolyte levels and kidney function.,Do not stop or adjust the infusion rate on your own.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER vs ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER, answered by our medical review team.
PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by Plasma-Lyte 148 and Dextrose 5% is an intravenous solution that provides maintenance fluid, electrolytes, and calories. Dextrose provides energy and prevents ketosis. Plasma-Lyte 148 contains electrolytes (sodium, potassium, magnesium, calcium, chloride, acetate, gluconate) to replace losses and maintain acid-base balance.. ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by Intravenous solution providing electrolytes (sodium, potassium, magnesium, chloride, acetate, phosphate) and dextrose for caloric supply. Acetate and phosphate serve as bicarbonate precursors to buffer metabolic acids. Dextrose provides energy and protein-sparing effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER and ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Intravenous Electrolyte Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER is: IV infusion at a rate of 10-20 m L/kg/hour, not to exceed 100 m L/hour in adults without cardiac or renal compromise; adjust based on fluid status and serum electrolytes.. The standard adult dose of ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion, rate determined by patient's fluid and electrolyte needs; typical adult dose: 1-2 L per 24 hours, adjusted based on clinical status.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER and ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. Plasma-Lyte 148 and Dextrose 5% is an intravenous electrolyte and carbohydrate solution. At therapeutic doses, no direct fetal toxicity or teratogenicity is expected as electrolyte. ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. Dextrose and electrolyte solutions are generally considered safe in pregnancy. Dextrose is a physiologic nutrient; no teratogenic effects are expected. Electrolytes are essential i. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.